在阴道粘膜上皮质细胞中进行基因传递的基因功能化多 (β-氨基乙) 混合系统
Xueqin Gao1, Dirong Dong2, Chong Zhang3,4
1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Pharmaceutics
|January 26, 2024
概括
这项研究引入了一种用于宫癌治疗的新型四分化奇托-g-多 (β-氨基) (QCP) 基因传递系统. 该QCP系统提高了低毒性阴道细胞的基因传染效率,为有效的基因疗法铺平了道路.
科学领域:
- 生物医学工程 生物医学工程
- 基因治疗 基因治疗
- 纳米技术 纳米技术
背景情况:
- 宫癌与持续的人类乳头瘤病毒 (HPV) 感染有关.
- 基因疗法为宫癌治疗提供了希望,但有效的阴道基因传递仍然是一个挑战.
- 基因编辑可以向HPV瘤基因,但输送系统需要改善粘膜组织.
研究的目的:
- 开发一种改进的基因传递系统,用于宫癌基因治疗的阴道输送.
- 为了增强基因载体的粘膜透和粘附.
- 评估一种新型四元化奇多-g-多 (β-氨基) (QCP) 混合系统的有效性和安全性.
主要方法:
- 合成了一种四元化奇托-g-多 (β-氨基) (QCP) 混合聚合物.
- 配制的多复合纳米粒子 (PQ-GFP NPs) 封装了绿色光蛋白 (GFP).
- 评估了体外 (HEK293T,ME180细胞) 和体内 (斯普拉格-道利大鼠) 的传染效率,与PEI 25 kD相比.
主要成果:
- 2:1的PBAE:QCP比率产生了最高的GFP转化效率,在体外显著超过PEI 25 kD.
- PBAE-QCP形成了直径为255.5nm的球形纳米粒子 (PQ-GFPNP).
- 在体内研究表明,由于增强的粘膜透和粘附,PBAE-QCP系统在阴道上皮细胞中表现出优异的GFP传染效率.
结论:
- 新的PBAE-QCP混合系统有效地将基因输送到阴道上皮细胞中.
- 四级化酸盐的结合增强了系统的粘膜透和粘附特性.
- PBAE-QCP系统显示出低毒性和良好的安全性,支持其用于宫癌基因治疗的潜力.
相关概念视频
Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


